Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 14:16:969-977.
doi: 10.2147/TCRM.S260377. eCollection 2020.

Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia

Auliya A Suwantika  1   2   3 , Angga P Kautsar  4   5 , Neily Zakiyah  1   2 , Rizky Abdulah  1   2 , Cornelis Boersma  6 , Maarten J Postma  2   5   6   7
Affiliations

Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia

Auliya A Suwantika et al. Ther Clin Risk Manag. .

Abstract

Background: The annual gross domestic expenditure on research and development (GERD) per capita of Indonesia ($24) remains relatively lower than the annual GERD per capita of neighboring countries, such as Vietnam ($36), Singapore ($1804), Malaysia ($361), and Thailand ($111).

Objective: The aim of this study was to conduct a cost-effectiveness analysis of spending on healthcare R&D to address the needs of developing innovative therapeutic products in Indonesia.

Methods: A decision tree model was developed by taking into account four stages of R&D: stage 1 from raw concept to feasibility, stage 2 from feasibility to development, stage 3 from development to early commercialization, and stage 4 from early to full commercialization. Considering a 3-year time horizon, a stage-dependent success rate was applied and analyses were conducted from a business perspective. Two scenarios were compared by assuming the government of Indonesia would increase GERD in health and medical sciences up to 2- and 3-times higher than the baseline (current situation) for the first and second scenario, respectively. Cost per number of innovative products in health and medical sciences was considered as the incremental cost-effectiveness ratio (ICER). Univariate sensitivity analysis was conducted to investigate the effects of different input parameters on the ICER.

Results: There was a statistically significant association (P-value<0.05) between countries' GERD in medical and health sciences with the number of innovative products. We estimated the ICER would be $8.50 million and $2.04 million per innovative product for the first and second scenario, respectively. The sensitivity analysis showed that the success rates in all stages and total GERD were the most influential parameters impacting the ICER.

Conclusion: The result showed that there was an association between GERD in medical and health sciences with the number of innovative products. In addition, the second scenario would be more cost-effective than the first scenario.

Keywords: GERD; ICER; cost-effective; health and medical sciences; innovative product.

PubMed Disclaimer

Conflict of interest statement

Professor Maarten Jacobus Postma reports Health-Ecore and PAG BV stocks, grants, and personal fees from Astra Zeneca, GSK, Boehringer Ingelheim, Janssen, MSD, Sanofi, and Sequiris, grants from BMS, WHO, and BioMerieux, and personal fees from Merck, Alexion, Asc Academics, Parexel, Pfizer, IQVIA, Novo Nordisk, and Sanofi, outside the submitted work. The authors report no other potential conflicts of interest for this work.

Figures

Figure 1
Figure 1
Decision tree model.
Figure 2
Figure 2
Linear regression analysis on countries’ GERD for medical and health sciences with the percentage of innovative products.
See this image and copyright information in PMC

References

    1. Health Sciences Authority. Regulatory overview of therapeutic products. Available from: https://www.hsa.gov.sg/therapeutic-products/overview. Accessed April10, 2020.
    1. UNESCO Institute for Statistics. Science, Technology and Innovation. Available from: http://data.uis.unesco.org/#. Accessed June10, 2020.
    1. Xu X, Zhang L, Chen L, Wei F. Does COVID-2019 have an impact on the purchase intention of commercial long-term care insurance among the elderly in China? Healthcare. 2020;8(2):126. - PMC - PubMed
    1. Xu X, Chen L. Projection of long-term care costs in china, 2020–2050: based on the bayesian quantile regression method. Sustainability. 2019;11:3530. doi:10.3390/su11133530 - DOI
    1. Xu X, Huang X, Zhang X, Chen L. Family economic burden of elderly chronic diseases: evidence from China. Healthcare. 2019;7:99. doi:10.3390/healthcare7030099 - DOI - PMC - PubMed